Compile Data Set for Download or QSAR
maximum 50k data
Found 41 Enz. Inhib. hit(s) with all data for entry = 2024
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM50182801((3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8...)
Affinity DataKi:  1.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285821((6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-...)
Affinity DataKi:  2.10nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285819((6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol...)
Affinity DataKi:  2.60nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285839((6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octan...)
Affinity DataKi:  6.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285820((6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane...)
Affinity DataKi:  7nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285834((6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol ...)
Affinity DataKi:  7.60nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285838((6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-dio...)
Affinity DataKi:  7.90nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285822((6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octan...)
Affinity DataKi:  8nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285843((6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2...)
Affinity DataKi:  15nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285844((6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspi...)
Affinity DataKi:  17nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285817(US10081601, Example 1.2 | US9796680, Example Table...)
Affinity DataKi:  1.40E+3nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285840((6R,7R,8S)-8-(but-1-yn-1-yl)-4-azaspiro[2.5]octane...)
Affinity DataIC50:  2.40nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285845((6R,7R,8S)-8-(4-fluorobut-1-yn-1-yl)-4-azaspiro[2....)
Affinity DataIC50:  2.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285819((6R,7R,8S)-8-methyl-4-azaspiro[2.5]octane-6,7-diol...)
Affinity DataIC50:  3.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285821((6R,7R,8S)-8-(fluoromethyl)-4-azaspiro[2.5]octane-...)
Affinity DataIC50:  6.20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285830((6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol ...)
Affinity DataIC50:  6.30nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285822((6R,7R,8S)-8-(difluoromethyl)-4-azaspiro[2.5]octan...)
Affinity DataIC50:  6.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285841((6R,7R,8S)-8-(pent-1-yn-1-yl)-4-azaspiro[2.5]octan...)
Affinity DataIC50:  6.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285834((6R,7R,8S)-8-vinyl-4-azaspiro[2.5]octane-6,7-diol ...)
Affinity DataIC50:  6.80nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285823((6R,7R,8S)-8-(chloromethyl)-4-azaspiro[2.5]octane-...)
Affinity DataIC50:  7.40nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285824((6R,7R,8R)-8-(methoxymethyl)-4-azaspiro[2.5]octane...)
Affinity DataIC50:  7.5nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM50182801((3R,4R,5R)-5-(Hydroxymethyl)piperidine-3,4-diol, 8...)
Affinity DataIC50:  8.20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285839((6R,7R,8S)-8-(prop-1-yn-1-yl)-4-azaspiro[2.5]octan...)
Affinity DataIC50:  9.70nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285846((6R,7R,8S)-8-(4,4-difluorobut-1-yn-1-yl)-4-azaspir...)
Affinity DataIC50:  11nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285838((6R,7R,8S)-8-ethynyl-4-azaspiro[2.5]octane-6,7-dio...)
Affinity DataIC50:  13nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285820((6R,7R,8R)-8-(hydroxymethyl)-4-azaspiro[2.5]octane...)
Affinity DataIC50:  13nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285831((6R,7R,8S)-8-propyl-4-azaspiro[2.5]octane-6,7-diol...)
Affinity DataIC50:  15nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285843((6R,7R,8S)-8-(3-fluoroprop-1-yn-1-yl)-4-azaspiro[2...)
Affinity DataIC50:  16nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285842((6R,7R,8S)-8-(3-hydroxyprop-1-yn-1-yl)-4-azaspiro[...)
Affinity DataIC50:  17nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285836((6R,7R,8S)-8-((E)-2-fluorovinyl)-4-azaspiro[2.5]oc...)
Affinity DataIC50:  20nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285844((6R,7R,8S)-8-(3,3-difluoroprop-1-yn-1-yl)-4-azaspi...)
Affinity DataIC50:  22nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285832((6R,7R,8S)-8-(2-fluoroethyl)-4-azaspiro[2.5]octane...)
Affinity DataIC50:  27nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285825((6R,7S,8S)-8-methoxy-4-azaspiro[2.5]octane-6,7-dio...)
Affinity DataIC50:  32nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285835((6R,7R,8S)-8-((Z)-2-fluorovinyl)-4-azaspiro[2.5]oc...)
Affinity DataIC50:  36nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM350905((6R,7R,8S)-8-(2,2-difluoroethyl)-4-azaspiro[2.5]oc...)
Affinity DataIC50:  56nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285826((6R,7R,8R)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-c...)
Affinity DataIC50:  75nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285837((6R,7R,8S)-8-(2,2-difluorovinyl)-4-azaspiro[2.5]oc...)
Affinity DataIC50:  75nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285818(US10081601, Example 1.3 | US9796680, Example Table...)
Affinity DataIC50:  222nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285828((6R,7R,8S)-6,7-dihydroxy-N-methyl-4-azaspiro[2.5]o...)
Affinity DataIC50:  264nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285829((6R,7R,8S)?N-cyclopropyl-6,7-dihydroxy-4-azaspiro[...)
Affinity DataIC50:  462nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysosomal acid glucosylceramidase(Homo sapiens (Human))
Alectos Therapeutics

US Patent
LigandPNGBDBM285827((6R,7R,8S)-6,7-dihydroxy-4-azaspiro[2.5]octane-8-c...)
Affinity DataIC50:  507nMAssay Description:Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 50 mM sodium phosphate 0.25% w/v sodium tau...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent